Primary driver of stomach cancer development identified

Apr 23, 2008

In a discovery that could lead to the development of new treatments for gastric cancer, scientists at the Melbourne Branch of the international Ludwig Institute for Cancer Research (LICR) have discovered what appears to be the primary driver of tumor development in the stomach. Results published today on-line in the Journal of Clinical Investigation show that inhibiting the signaling cascade initiated by the IL-11 protein prevented the development of inflammation, hyperplasia (an abnormal increase in the number of cells) and tumor formation in pre-clinical models of gastric cancer.

Gastric cancer is the second most common cause of cancer-related deaths around the world, and has been shown previously to be correlated with chronic inflammation. Persistent activation of the Stat3 protein, which is known to play roles in inflammation-associated carcinogenesis, is commonly found in gastric and many other types of cancer.

Until now, however, the underlying cause of hyperactive Stat3 was unknown. The current study demonstrates that IL-11 promotes chronic inflammation and associated tumorigenesis in the stomach by inducing excessive activation of Stat3. The study used both genetic and pharmacologic inhibitors to show that blocking this signaling pathway prevented or reduced tumorigenesis in a mouse model of inflammation-dependent human gastric cancer.

“Although we made this discovery in a mouse model, we expect it to be highly relevant to the clinic because of the striking similarity in gastric tumour development and appearance between mice and men,” says the lead author of the study, Professor Matthias Ernst from the LICR Melbourne Branch. “The clear link between inhibition of IL-11/Stat3 activity and suppression of gastric tumorigenesis that we identified supports the further development of pharmacologic agents that target these molecules for the treatment of gastric and potentially other cancers. We believe that we have a very relevant model in our hand for the preclinical assessment of such compounds as well as for the identification of potential markers that may ultimately help in the early detection of disease.

Source: Ludwig Institute for Cancer Research

Explore further: Chronic inflammation linked to 'high-grade' prostate cancer

add to favorites email to friend print save as pdf

Related Stories

Scientists solve a sticky problem

Jan 06, 2014

(Medical Xpress)—Scientists have uncovered how an ulcer causing stomach bacteria, that has been linked to gastric cancer, sticks to and infects the lining of the stomach and gut.

Chlamydia promotes gene mutations

Jun 20, 2013

Chlamydia trachomatis is a human pathogen that is the leading cause of bacterial sexually transmitted disease worldwide with more than 90 million new cases of genital infections occurring each year. About ...

Early indicators of lung cancer probed in new study

Jun 04, 2013

(Phys.org) —Many of the critical processes underlying cancer formation and eventual metastasis to other organs remain mysterious. In the quest for earlier diagnoses and more effective treatment, intensive ...

X-rays pinpoint drug target for Helicobacter pylori

Dec 10, 2012

(Phys.org)—Experiments at the U.S. Department of Energy's (DOE) SLAC National Accelerator Laboratory have revealed a potential new way to attack common stomach bacteria that cause ulcers and significantly ...

Recommended for you

Unraveling the 'black ribbon' around lung cancer

Apr 17, 2014

It's not uncommon these days to find a colored ribbon representing a disease. A pink ribbon is well known to signify breast cancer. But what color ribbon does one think of with lung cancer?

User comments : 0

More news stories

Suddenly health insurance is not for sale

(HealthDay)— Darlene Tucker, an independent insurance broker in Scotts Hill, Tenn., says health insurers in her area aren't selling policies year-round anymore.